Lymphovascular invasion as a criterion for adjuvant chemotherapy for FIGO stage I-IIa clear cell carcinoma, mucinous,low grade serous and low grade endometrioid ovarian cancer.

Fiche publication

Date publication

juillet 2021

Journal

Journal of gynecology obstetrics and human reproduction

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles , Pr AKLADIOS Chérif

Tous les auteurs :
Delvallée J, Cancel M, Body G, Bendifallah S, Touboul C, Dabi Y, Collinet P, Coutant C, Akladios C, Lavoué V, Bolze PA, Huchon C, Bricou A, Canlorbe G, Ballester M, Carcopino X, Mimoun C, Darai E, Ouldamer L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34224900

Résumé

The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients managed for stage I-IIa clear cell carcinoma, mucinous, low-grade serous and low-grade endometrioid ovarian cancer MATERIAL AND METHODS: Retrospective multicentre study of the research group FRANCOGYN between January 2001 and December 2018. All patients managed for stage I-IIa clear cell carcinoma, mucinous /low grade serous and endometrioid ovarian cancer and for whom the presence of histological slides for the review of LVSI was available, were included. Patient's characteristics with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A cox analysis for OS and RFS analysis were performed in all population.